Difficult-to-Express Proteins Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Difficult-to-Express Proteins Market is segmented By Protein (Proteases, Kinases, Membrane Proteins, Others), By Technology (Cell-free Protein Synthesis, Prokaryotic Expression Systems, SUMO Fusion System, Gene Fusion Systems, Others), By Application (Drug Discovery, Protein Purification, Protein Therapeutics, Disease Diagnostics and Monitoring, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Difficult-to-Express Proteins Market Size

The Global Difficult-to-Express Proteins Market reached USD 4,007.6 million in 2022 and is projected to witness lucrative growth by reaching up to USD 9,052.1 million by 2031. The difficult-to-express proteins market is expected to exhibit a CAGR of 11.0% during the forecast period (2024-2031). 

Prokaryotic expression system research and development have increased due to the rising demand for recombinant proteins and this trend is anticipated to fuel market expansion over the forecast period.

The mass production of a protein using E. coli bacteria, the most popular artificial expression host, has resulted in the expansion of prokaryotic expression systems. Because of its genomic and physiological sequencing system, which makes cloning easier and makes the E. coli host the most well-liked in the pharmaceutical industry, E. coli is widely used in the difficult-to-express proteins market.

Difficult-to-express proteins are the proteins whose synthesis is difficult in established in vivo protein production platforms. Moreover, it is often challenging to express these proteins in heterologous expression systems due to their inherent properties, the tendency to aggregate and form inclusion bodies, intrinsic nature, and the difficulty for the foreign host to fold a protein correctly. Special types of proteins such as membrane proteins, proteases, kinases, and others are difficult-to-express proteins included in the scope of the difficult-to-express proteins market.

Difficult-to-Express Proteins Market Summary

For more details on this report - Request for Sample

Difficult-to-Express Proteins Market Trends

The Advancements in Cell-free Protein Synthesis Platforms are Boosting the Global Difficult-to-Express Proteins Market Growth.

The advancements in cell-free protein synthesis platforms achieve qualitative and quantitative results are driving the difficult-to-express-proteins market during the forecast period. For instance, according to an article published in Genetic Engineering & Biotechnology News in August 2022, researchers at the California Polytechnic State University reported that eliminating the lac operators (lacO) and N-terminal tags in the vector backbone allowed the pET vector to sustain elevated titers of protein expression for cell-free protein synthesis and, thus, produce higher yields.

The High Cost of Systems and Difficulty in Analyzing Targets are Hampering the Growth of the Global Difficult-to-Express Proteins Market.

The high cost of systems and difficulty in analyzing target hinders the difficult-to-express protein market growth. Also, high-quality bioactive proteins are produced at a large scale utilizing protein expression systems. Therefore, the total production cost of bioactive proteins increases significantly due to the high cost of reagents. For instance, the Champion pET SUMO Expression System manufactured by Thermo Fisher Scientific Inc. costs around USD 1,467.4

Difficult-to-Express Proteins Market Segment Analysis

The global difficult-to-express proteins market is segmented based on proteins, technology, applications, and region.

The Membrane Protein Segment is Expected to Hold a Dominant Position in the Market over the Forecast Period.

The membrane protein segment held about 36.1% of the total difficult-to-express proteins market in 2022 and it is estimated to grow throughout the forecast period owing to the increasing focus on research and development of intellectual resources.

For instance, in September 2022, Salipro Biotech AB, a Swedish biotech company, obtained a Granted patent in the U.S. Patent and Trademark Office and China National Intellectual Property Administration for Direct Extraction of Membrane Proteins and Library Generation. 

This patent strengthens Salipro Biotech's global intellectual property portfolio, with various patents already granted in the U.S., EU, China, and Japan. Moreover, in October 2022, the University of Chicago and the MRC Laboratory of Molecular Biology (Cambridge, UK) collaborated to study the synthesis of membrane proteins.

Source: DataM Intelligence Analysis (2023)

Difficult-to-Express Proteins Market Geographical Share

North America Holds a Dominant Position in the Global Difficult-to-Express Proteins Market.

North America occupied the highest share of the difficult-to-express proteins accounting for around 41.2% in 2022 and is estimated to increase to 41.7% by 2030. Owing to the presence of key market players holding the majority of the difficult-to-express proteins market share via performing distinct market tactics such as collaborations, acquisition, merger, and securing funding and investments among Disease Diagnostics and Monitoring.

For instance, in March 2022, Reaction Biology, which offers a comprehensive spectrum of drug discovery CRO services including fee-for-service preclinical drug testing and integrated drug development announced the closing of a significant investment from Cobepa, an international private equity firm, to fuel the Company's continued growth and service line expansion.

Source: DataM Intelligence Analysis (2023)

Difficult-to-Express Proteins Companies

The major global players in the market include Reaction Biology (Cobepa), LifeSensors Inc., Lucigen(LGC Group), BioLegend, Inc.(PerkinElmer Inc.), OriGene Technologies, Inc., R&D Systems, Enzo Life Sciences, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Inc. and Merck KGaA, among others.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine is estimated to have a minimal impact on the global difficult-to-express proteins market owing to the absence of key market players in this region. However, the impact of the import and export of raw materials, products, and devices is anticipated to have little influence over the global difficult-to-express proteins market in the forecast period.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employing freezes during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. The recession has led to a decrease in research investments which has negatively impacted the market growth in the past few years.

Artificial Intelligence Impact Analysis

According to an article sourced from the University of Washington School of Medicine/UW Medicine published in February 2023, Scientists have utilized machine learning to construct brand-new enzymes, which are proteins that boost chemical reactions. The research team developed deep-learning, artificial intelligence algorithms that constructed light-emitting enzymes called luciferases. Laboratory testing proved that the new enzymes can identify distinct chemicals and radiate light with remarkable efficiency. Such developments in protein research with AI are expected to positively impact the global difficult-to-express protein market in the upcoming years.

Key Developments

• In September 2022, LifeSensors Inc., a biotechnology company leading the development of innovative research tools and services for the ubiquitin and ubiquitin-like protein pathways declared that lifesensors had published a seminal paper: Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation. 
• In January 2022, Thermo Fisher Scientific Inc., an American manufacturer and supplier of scientific laboratory instrumentation, reagents and consumables, and software services acquired PeproTech, a manufacturer of high-grade recombinant cytokines and growth characteristics sustain life science investigation, cellular therapy and regenerative medicine for around USD 1.85 billion. 
• Via this investment, PeproTech's recombinant proteins portfolio is expected to complement Thermo Fisher's cell culture media products and further help Thermo Fisher to deliver its clients' substantial advantages via a combined offering. 
• In January 2022, Merck KGaA, a top science and technology corporation, functions across Healthcare, Life Science, and Electronics completed the acquisition of Exelead, a biopharmaceutical agreement development and manufacturing association (CDMO), for around USD 780 million.

Why Purchase the Report?

• To visualize the global Difficult-to-Express Proteins market segmentation based on Proteins, Technology, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of Difficult-to-Express Proteins market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The Global Difficult-to-Express Proteins Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies